Seaport Therapeutics Reports Positive Phase 1 GlyphAllo Data
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. reported positive topline results from a Phase 1 driving simulation trial...
Phase 2b
Advertisement
Seaport Therapeutics Advances GlyphAllo in Major Depression
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. announced positive topline results from a Phase 1 driving simulation trial...
Can-Fite Reports Namodenoson Liver Cirrhosis Case
RAMAT GAN, Israel — September 9, 2026 Can-Fite BioPharma Ltd. announced publication of a peer-reviewed case report describing clinical...
Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis
PALO ALTO, Calif. and NEW YORK — September 8, 2026 Evommune, Inc. announced top-line results from its randomized, double-blind,...
Structure Therapeutics Reports Positive Oral Weight-Loss Data
SAN FRANCISCO — September 8, 2026 Structure Therapeutics reported positive clinical data across its two lead oral small-molecule programs...
Advertisements
Epicyt Pharma Advances BAFA Toward Phase 2b Development
GOTHENBURG, Sweden — September 8, 2026 Epicyt Pharma AB reported positive topline results from its Phase 1/2a first-in-human study...
SynAct Pharma Advances Resomelagon Toward Phase 3 in RA
Lund, Sweden, September 7, 2026 SynAct Pharma AB has reported further analyses from its Phase 2b ADVANCE clinical trial...
Alumis Advances Envudeucitinib Toward Phase 3 in SLE
SAN FRANCISCO, Sept. 1, 2026 Alumis Inc. announced topline results from its Phase 2b LUMUS trial of envudeucitinib in...
Kymera Therapeutics Advances KT-621 in Atopic Dermatitis
WATERTOWN, Mass., Sept. 1, 2026 Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class...
Osivax, GC Biopharma Partner on Next-Gen Flu Vaccine
Lyon, France and Yongin, Republic of Korea, Aug. 26, 2026 Osivax, a clinical-stage biopharmaceutical company developing broad-spectrum influenza vaccines,...
Advertisement
